Drug Insight: using statins to treat neuroinflammatory disease (Q34560503)

3 August 2017

1 reference

title

Drug Insight: using statins to treat neuroinflammatory disease (English)

1 reference

3 August 2017

Martin S Weber

1

1 reference

3 August 2017

Thomas Prod'homme

series ordinal

2

1 reference

3 August 2017

Lawrence Steinman

series ordinal

3

1 reference

3 August 2017

Scott S Zamvil

series ordinal

4

1 reference

3 August 2017

publication date

1 December 2005

1 reference

Nature Clinical Practice Neurology

3 August 2017

published in

1 reference

3 August 2017

volume

1

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

106-112

1 reference

Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Atorvastatin induces T cell anergy via phosphorylation of ERK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Statins and risk of polyneuropathy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

Effects of statins on triglyceride metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Immune therapy for autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Class II transactivator regulates the expression of multiple genes involved in antigen presentation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Costimulation: building an immunological synapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Functional diversity of helper T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Matrix metalloproteinases and diseases of the CNS.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Therapeutic potential of lovastatin in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0047

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0047

1 reference

3 August 2017

1 reference